Wall St rises, buoyed by drug sector deal

Wall St rises, buoyed by drug sector deal
Comment E-mail Print Share
First Published: Tue, Jan 27 2009. 08 37 AM IST
Updated: Tue, Jan 27 2009. 08 37 AM IST
New York: US stocks rose in choppy trade on Monday, lifted by optimism over a $68 billion takeover in the drug industry that offset a grim warning about the year ahead from Caterpillar and worries over the state of the financial sector.
A rare piece of good news for the recession-hit economy also helped sentiment, as sales of existing US homes unexpectedly jumped 6.5% in December. The Dow Jones index of home builders’ stocks rose 2.7%.
Pfizer Inc, the world’s biggest drug maker, said it would buy rival Wyeth for about $68 billion, suggesting that some companies are attractively valued after a dismal 2008.
“We haven’t seen any big deals in a while (so) it’s an indication that there is potential for some deals to get done,” said Kurt Brunner, portfolio manager at Swarthmore Group in Philadelphia.
Caterpillar was the Dow’s top drag after the heavy equipment maker forecast its 2009 profit would drop significantly from 2008 and said it would cut nearly 20,000 jobs. Caterpillar shed 8.4% to $32.67.
The Dow Jones industrial average rose 38.47 points, or 0.48%, to 8,116.03. The Standard & Poor’s 500 Index added 4.62 points, or 0.56%, to 836.57. The Nasdaq Composite Index gained 12.17 points, or 0.82%, to 1,489.46.
The modest gains enabled the Dow to break a two-day losing streak. The broad S&P 500 is down more than 7% for the year so far, but it is up about 11% from the 11-year lows hit in late November. The S&P started the year up about 20% from those lows.
Home Depot was among a spate of companies to announce deep job cuts, with the world’s largest home-improvement retailer slashing 7,000 jobs. The Dow component rose 4.7% to $22.73.
Companies across all sectors have been chopping jobs as they deal with slowing consumer demand and the fallout from the global economic downturn.
Pfizer tumbled 10.3% to $15.65 on worries over what benefits - if any - it may reap from the acquisition, which had been rumored since last week. It is the biggest non-financial deal since March 2008. Wyeth retreated from earlier gains, falling 0.8% to $43.39.
“I think there might be some questions about, all in all, what does it bring them,” Brunner said of the Pfizer-Wyeth deal.
Financials turned lower in the afternoon and capped gains as investors fretted over whether the sector, which is at the heart of the credit crisis, will need to raise yet more capital. The S&P financial index fell 2.1%.
Among financial-sector laggards, Regions Financial Corp tumbled 12% to $4.10 after influential banking analyst Richard Bove said it may slash its dividend by 90%.
Volume was moderate on the New York Stock Exchange, where about 1.27 billion shares changed hands, below last year’s estimated daily average of 1.49 billion. On the Nasdaq, about 1.84 billion shares traded below last year’s daily average of 2.28 billion.
Comment E-mail Print Share
First Published: Tue, Jan 27 2009. 08 37 AM IST
More Topics: Markets | US | Stocks | Wall Street | Dow Jones |